<DOC>
	<DOCNO>NCT00493025</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Gefitinib may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . Giving gefitinib surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well give paclitaxel , cisplatin , gefitinib , radiation therapy follow surgery gefitinib work treat patient locally advanced cancer esophagus gastroesophageal junction remove surgery .</brief_summary>
	<brief_title>Paclitaxel , Cisplatin , Gefitinib , Radiation Therapy Followed Surgery Gefitinib Treating Patients With Locally Advanced Cancer Esophagus Gastroesophageal Junction That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathologic complete response rate patient resectable , locally advanced adenocarcinoma esophagus gastroesophageal junction treat neoadjuvant paclitaxel , cisplatin , gefitinib , radiotherapy follow surgery adjuvant gefitinib . Secondary - Determine survival patient treat regimen . - Determine safety tolerability regimen patient . - Determine time disease progression patient treat regimen . - Determine plasma pharmacokinetics unbound gefitinib patient . - Conduct exploratory study determine EGFR pathway component expression activation correlate response therapy survival patient . - Determine treatment gefitinib alters EGFR pathway patient . OUTLINE : This prospective study . - Neoadjuvant therapy : Patients receive oral gefitinib begin 14 day prior start chemoradiotherapy continue 7 day prior surgery ( 10-12 week ) . Patients also receive paclitaxel IV 1 hour cisplatin IV 2-3 hour day 1 , 8 , 15 , 22 , 29 . Patients also undergo radiotherapy 5 day week 5 week . - Surgery : Patients undergo surgical resection 4-6 week completion neoadjuvant therapy . - Adjuvant therapy : Patients receive gefitinib day begin 2-8 week surgery continue 1 year absence disease progression unacceptable toxicity . Blood sample obtain baseline periodically study pharmacokinetic study . Tumor tissue sample obtain core biopsy baseline biomarker correlative study . Samples analyze IHC measure expression activation EGFR-signaling pathway biomarkers pretreatment esophageal tumor tissue , include EGFR phosphorylated ( p ) -EGFR , ERK p-ERK , Akt p-Akt , p70s6k p-p70s6k , p27 . After completion study therapy , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma esophagus gastroesophageal junction meeting follow criterion : Newly diagnose disease Surgically resectable tumor Primary esophageal tumor &lt; 20 cm incisor Tumor extend ≤ 2 cm cardia Stage T23 , N01 , M01a tumor , determine image study biopsy Documentation endoscopic ultrasound , endoscopy , CT scan chest abdomen require Any lesion suspicious metastasis must biopsied M1a disease ( i.e. , celiac nodal metastasis ) allow eligibility criterion meet T4 disease ( i.e. , involvement pleura , pericardium , diaphragm ) allow provide consider resectable No CNS metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocyte count &gt; 1,000/mm³ Platelet count &gt; 75,000/mm³ Creatinine clearance &gt; 60 mL/min Total bilirubin &lt; 1.5 mg/dL No concurrent illness likely preclude protocol therapy surgical resection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No known severe hypersensitivity gefitinib excipients No evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) No evidence significant clinical disorder laboratory find would preclude study participation No evidence clinically active interstitial lung disease Patients chronic , stable radiographic change asymptomatic eligible No prior concurrent malignancy except basal cell squamous cell skin cancer , cervical cancer , curatively treated malignancy patient diseasefree survival prognosis &gt; 5 year No preexist peripheral neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : No incomplete heal prior oncologic major surgery No prior chemotherapy , radiotherapy , surgery cancer Endoscopy biopsy dilation allow More 30 day since prior nonapproved investigational drug No concurrent phenytoin , carbamazepine , barbiturate , rifampin , phenobarbital , Hypericum perforatum ( St. John 's wort ) No concurrent oral retinoids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>